SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat ...

Investors in Nurix Therapeutics Inc (Symbol: NRIX) saw new options begin trading this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

$NRIX insiders have traded $NRIX stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales. Here’s a ...

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like NX-5948.

Check the time stamp on this data. Updated AI-Generated Signals for Nurix Therapeutics Inc. (NRIX) available here: NRIX. Type ...

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report)‘s stock had its “overweight” rating restated by Stephens in a report issued on Tuesday,Benzinga reports. They currently have a $31.00 target price on ...

Nurix Therapeutics (NRIX) focuses on protein degradation in cancer treatment, with a current valuation of $1.4 billion and promising early-stage clinical data. NX-5948, a BTK degrader, shows high ...

Since it has a market capitalisation of US$1.4b, Nurix Therapeutics' US$107m in cash burn equates to about 7.9% of its market value. Given that is a rather small percentage, it would probably be ...

In a report released today, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We are thrilled to have John join the Nurix team as we prepare to launch our pivotal clinical program for NX-5948 in chronic lymphocytic leukemia and potentially other B-cell malignancies,” said ...